European ruling on Gilenya expected soon; NICE rejects first-line Avastin in breast cancer;

 @FiercePharma: Pfizer's still working with Nestle and Danone in nutrition-unit sale, Bloomberg says, though Danone thinks it won't win. Article | Follow @FiercePharma

> After a safety review, European regulators are expected to allow the Novartis ($NVS) multiple sclerosis pill Gilenya to remain on the market without significantly stricter warnings; a decision could come this week. Story

> The U.K.'s cost-effectiveness watchdog declined to recommend Roche's ($RHHBY) Avastin as a first-line treatment for metastatic breast cancer. News

> Canada's Supreme ourt is set to hear a challenge to Pfizer's ($PFE) Viagra patent from generics maker Teva ($TEVA). More

> CSL Biotherapies pulled six batches of Albumex on contamination problems, while Hospira recalled one lot of morphine injection because of overfilled syringes. Item

> Teva Pharmaceutical Industries won an appeal in a patent fight over the branded drug Amrix that the Israeli drugmaker acquired in its Cephalon buyout. Report

> Prescription drug spending growth slowed slightly last year as new generics hit the market, Express Scripts said. Article

Biotech News

 @FierceBiotech: Fierce's Top 10 Late-Stage Cancer Drugs -- 2012. Report | Follow @FierceBiotech

 @JohnCFierce: GSK doubles down on drug discovery collaboration with FivePrime, a Fierce 15 company in 2004. News | Follow @JohnCFierce

 @RyanMFierce: Google VC fuels Series A round for pharma software startup Wingu, aims to capitalize on open R&D trend. Story | Follow @RyanMFierce

> Abbott touts positive Parkinson's PhIII as pharma split looms. More

> Crucell and Royal DSM pull the plug on biosimilar JV. News

> J&J and Bristol-Myers ally on another potential hep C blockbuster. Article

> Roche says it won't extend Illumina offer past Friday deadline. Item

Medical Devices News

 @FierceMedDev: Abbott Breakup Plans Are on Target as Profit Tops Estimates | Bloomberg. Article | Follow @FierceMedDev

> As tax looms, device companies mull layoffs, cuts. More

> St. Jude Medical ekes out Q1 sales increase. Story

Drug Delivery News

> Meet the new editor of FierceDrugDelivery. Item

> Novo: Delivery devices could make biosimilars unsafe. More

> Dutch firm gets Fox Foundation funding for PD tech. Story

> BDSI gets patent for anti-opioid film. News

> pSivida stock rallies after Durasert partnerships. Article

Biomarkers News

> Saliva test could aid dentists in oral cancer diagnosis. Story

> RNA markers for blast-induced traumatic brain injury. Item

> Postmenopausal osteoporosis fingerprinted by miRNAs. More

> Chemo-resistance proteins mark defiant breast tumors. Article

And Finally... Brain scans may be able to predict weight gain based on responses to appetite-driven cues. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.